Breaking News

Xceleron, Kinetigen in Pharmacokinetic Pact

February 26, 2013

Aims to provide simpler, more robust early investigations

Xceleron has partnered with Kinetigen, a clinical pharmacology consulting firm specializing in pharmacokinetics, to offer drug developers solutions for robust and cost-effective investigations of Phase I drug pharmacokinetics. Kinetigen will provide its complex PK analyses and overall clinical pharmacology strategies and Xceleron will use its Accelerator Mass Spectrometry (AMS) to gain analytical insight across a broad range of asset classes and matrix types.
 
“At Xceleron, we believe that technology can get life-changing drugs to people who need them, sooner and at a lower cost. This partnership with Kinetigen will help our clients do that by efficiently and cost-effectively answering critical questions earlier,” said Dr. Michael Butler, chief executive officer of Xceleron.
 
“Our partnership with Xceleron is very synergistic,” said Dr. Geoffrey Banks, chief executive officer of Kinetigen.  “Matching Kinetigen’s PK expertise with Xceleron’s AMS technology is a ‘win-win’ situation for clients seeking more robust options for analysis and interpretation of Phase I PK data.”

Related Compliance:

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials